Rituximab-induced serum sickness in multiple sclerosis patients.

Abstract:

:Rituximab is a chimeric anti-CD20 monoclonal antibody that is an effective therapy for multiple sclerosis. Rituximab has been associated with the development of serum sickness (type III hypersensitivity) characterized by arthralgia, fever, and rash during the treatment of other conditions, such as rheumatoid arthritis. Here we describe serum sickness associated with rituximab in multiple sclerosis patients and discuss both the management of serum sickness itself and implications for utilizing alternative anti-CD20 monoclonal antibodies for disease management in this patient population.

authors

Wolf AB,Ryerson LZ,Pandey K,McGettigan BM,Vollmer T,Corboy JR,Alvarez E

doi

10.1016/j.msard.2019.101402

subject

Has Abstract

pub_date

2019-11-01 00:00:00

pages

101402

eissn

2211-0348

issn

2211-0356

pii

S2211-0348(19)30382-7

journal_volume

36

pub_type

杂志文章
  • Racial differences in retinal neurodegeneration as a surrogate marker for cortical atrophy in multiple sclerosis.

    abstract:BACKGROUND:Multiple sclerosis (MS) has both an inflammatory and a neurodegenerative component, with gray matter (GM) atrophy being an important contributor to disability. Optical coherence tomography (OCT) may serve as a prognostic tool for neuroaxonal health by measuring ganglion cell inner plexiform layer (GCIPL) thi...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.04.001

    authors: Lichtman-Mikol S,Razmjou S,Yarraguntla K,Bao F,Santiago-Martinez C,Seraji-Bozorgzad N,Bernitsas E

    更新日期:2019-06-01 00:00:00

  • Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study.

    abstract:BACKGROUND:Growing evidence supports the efficacy of restorative cognitive training in people with multiple sclerosis (PwMS), but the effects vary across individuals. Differences in treatment efficacy may be related to baseline individual differences. We investigated clinical characteristics and MRI variables to predic...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.06.026

    authors: Fuchs TA,Ziccardi S,Dwyer MG,Charvet LE,Bartnik A,Campbell R,Escobar J,Hojnacki D,Kolb C,Oship D,Pol J,Shaw MT,Wojcik C,Yasin F,Weinstock-Guttman B,Zivadinov R,Benedict RHB

    更新日期:2019-09-01 00:00:00

  • Development of a brief clinician-reported outcome measure of multiple sclerosis signs and symptoms: The Clinician Rating of Multiple Sclerosis (CRoMS).

    abstract:OBJECTIVE:No available assessment tool offers a brief and psychometrically sound way for clinicians to quantify assessment of MS in a typical office visit. The objective of this study was to develop a brief clinician-reported outcome measure of MS signs and symptoms to standardize and quantify assessments that occur du...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.06.024

    authors: Matza LS,Stewart KD,Phillips G,Delio P,Naismith RT

    更新日期:2019-10-01 00:00:00

  • Cardiac autonomic function during postural changes and exercise in people with multiple sclerosis: A cross-sectional study.

    abstract:BACKGROUND:People with multiple sclerosis (PwMS) often develop an autonomic dysfunction (AD), which onset should be assessed early at a subclinical level, as it may interfere with pharmacological treatments and exercise. OBJECTIVE:To evaluate basal cardiac autonomic tone, its modulations during sit-to-stand, sub-maxim...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.06.003

    authors: Gervasoni E,Bove M,Sinatra M,Grosso C,Rovaris M,Cattaneo D,Merati G

    更新日期:2018-08-01 00:00:00

  • To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis.

    abstract:BACKGROUND:The frequency and long-term prognosis of relapsing multiple sclerosis (RMS) never receiving disease-modifying treatment (DMT) is unclear. METHODS:We included 1186 RMS patients with a mean of 17.4 years follow-up and divided them into patients treated with any DMT (DMT) and patients untreated by shared (USD)...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.101908

    authors: Bsteh G,Hegen H,Dosser C,Auer M,Berek K,Wurth S,Zinganell A,Di Pauli F,Deisenhammer F,Berger T

    更新日期:2019-12-23 00:00:00

  • Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review.

    abstract:INTRODUCTION:Natalizumab break exposes multiple sclerosis (MS) patients to a high risk of disease reactivation or rebound, whose prevention and treatment constitute a clinical challenge. CASE PRESENTATION:We describe a dramatic case of MS rebound, characterized by the development of severe neurological and psychiatric...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2019.03.002

    authors: Federle L,Puthenparampil M,Stenta G,Paolo G,Francesco P

    更新日期:2019-05-01 00:00:00

  • Olfactory dysfunction in multiple sclerosis.

    abstract:BACKGROUND:Multiple sclerosis (MS) is a common chronic neurological disease that causes disability. MS can have various clinical manifestations, one of which is olfactory dysfunction. In clinical practice, olfactory disturbances are usually underdiagnosed. The aim of our study is to assess olfactory function and its re...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.02.032

    authors: Atalar AÇ,Erdal Y,Tekin B,Yıldız M,Akdoğan Ö,Emre U

    更新日期:2018-04-01 00:00:00

  • The prevalence of cognitive impairment in patients with neuromyelitis optica spectrum disorders (NMOSD): A systematic review and meta-analysis.

    abstract:OBJECTIVE:To estimate pooled prevalence of cognitive impairment in neuromyelitis opticaspectrum disorders (NMOSD) cases. METHODS:We searched PubMed, Scopus, EMBASE, Web of Science, and google scholar. We also searched the gray literature including references of the included studies, and conference abstracts which were...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2021.102757

    authors: Moghadasi AN,Mirmosayyeb O,Mohammadi A,Sahraian MA,Ghajarzadeh M

    更新日期:2021-01-15 00:00:00

  • Temporal evolution of acute multiple sclerosis lesions on serial sodium (23Na) MRI.

    abstract:BACKGROUND:Several studies have reported the characteristics of acute multiple sclerosis (MS) lesions on diffusion-weighted magnetic resonance imaging (DWI MRI). Current publications reported a transient reduction of the apparent diffusion coefficient (ADC) delineating an early phase of lesion evolution, before increas...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.01.027

    authors: Eisele P,Konstandin S,Szabo K,Ebert A,Roßmanith C,Paschke N,Kerschensteiner M,Platten M,Schoenberg SO,Schad LR,Gass A

    更新日期:2019-04-01 00:00:00

  • Treating acute ischemic stroke in a patient with multiple sclerosis: A challenging issue.

    abstract::Multiple sclerosis (MS) is a chronic disease characterized by inflammation, demyelination and neurodegeneration in the central nervous system. Recent studies suggested that patients with MS might have a greater risk of ischaemic stroke (IS). IS treatment with intravenous alteplase (IVA) in MS has rarely been reported....

    journal_title:Multiple sclerosis and related disorders

    pub_type:

    doi:10.1016/j.msard.2020.101962

    authors: de Falco A,De Simone M,d'Onofrio F,Spitaleri D,de Falco FA

    更新日期:2020-05-01 00:00:00

  • Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.

    abstract:BACKGROUND:The role that dietary interventions can play in multiple sclerosis (MS) management is of huge interest amongst patients and researchers but data evaluating this is limited. Possible effects of a very-low-fat, plant-based dietary intervention on MS related progression and disease activity as measured by brain...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.msard.2016.07.001

    authors: Yadav V,Marracci G,Kim E,Spain R,Cameron M,Overs S,Riddehough A,Li DK,McDougall J,Lovera J,Murchison C,Bourdette D

    更新日期:2016-09-01 00:00:00

  • The long-term impact of multiple sclerosis on the risk of divorce.

    abstract:BACKGROUND:Several studies have investigated the impact of multiple sclerosis (MS) on the risk of divorce. However, current evidence is inconclusive and limited by e.g. small sample populations, short follow-up, and/or lack of a control group. The objective of this retrospective, observational study was to estimate the...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.07.002

    authors: Landfeldt E,Castelo-Branco A,Svedbom A,Löfroth E,Kavaliunas A,Hillert J

    更新日期:2018-08-01 00:00:00

  • Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?

    abstract:INTRODUCTION:Interferon-beta (IFNβ) is currently the most used disease-modifying treatment for relapsing-remitting multiple sclerosis (RRMS), but it can lead to the production of neutralising antibodies (NABs) against IFNβ. CLINICAL CASE:A lady with a past history of genital herpes was diagnosed with RRMS, started IFN...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2014.11.007

    authors: Fine D,Dattani A,Moreira I,Giovannoni G,Marta M

    更新日期:2015-01-01 00:00:00

  • Hypocomplementemic urticarial vasculitis and multiple Sclerosis: A rare association or an atypical presentation?

    abstract:BACKGROUND:Multiple Sclerosis (MS) has been associated with several immune-mediated diseases but the mechanisms that explain such associations, as well as their implications in clinical practice and treatment are rarely discussed. CASE PRESENTATION:We report the case of a patient with a history of MS since she was 27 ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.02.020

    authors: Durães J,Gonçalo M,Sousa L,Macário MC

    更新日期:2019-05-01 00:00:00

  • Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.

    abstract:BACKGROUND:Patient-reported outcomes (PROs) provide information on treatment effects from the patient's perspective that complement outcomes on clinical measures. In DECIDE, daclizumab demonstrated superior efficacy in reducing relapses, 24-week confirmed disability progression, and brain lesions (assessed by magnetic ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.msard.2016.11.005

    authors: Liu Y,Vollmer T,Havrdova E,Riester K,Lee A,Phillips G,Wang P,Sabatella G

    更新日期:2017-01-01 00:00:00

  • Favorable outcome of interferon-beta associated thrombotic microangiopathy following treatment with corticosteroids, plasma exchange and rituximab: A case report.

    abstract::Thrombotic microangiopathy (TMA) is a rare but increasingly recognized complication of interferon-beta therapy, which can be associated with serious sequelae. We report on a 53-year-old woman with a longstanding history of relapsing-remitting multiple sclerosis, who developed TMA after 15 years of high-dose treatment ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.09.002

    authors: Gerischer LM,Siebert E,Janke O,Jungehuelsing GJ,Ruprecht K

    更新日期:2016-11-01 00:00:00

  • Secondary hypersomnia as an initial manifestation of neuromyelitis optica spectrum disorders.

    abstract::The identification of AQP4-IgG, a specific and pathogenic antibody of NMO/SD has led to a broadening of the clinical spectrum of manifestations of NMO/SD including the presence of encephalic symptoms. Lesions are often distributed on peri‑ependymal area and sometimes affected the diencephalon leading to sleep disorder...

    journal_title:Multiple sclerosis and related disorders

    pub_type:

    doi:10.1016/j.msard.2019.101869

    authors: Beigneux Y,Arnulf I,Guillaume-Jugnot P,Leu-Semenescu S,Maillart E,Lubetzki C,Benveniste O,Papeix C

    更新日期:2020-02-01 00:00:00

  • Neurosarcoidosis as an MS Mimic: The trials and tribulations of making a diagnosis.

    abstract::The clinical presentation of neurosarcoidosis is varied as multiple levels of the neuraxis may be affected. When central nervous system involvement occurs, making an accurate diagnosis of the condition can be challenging, especially given the current definition for definite neurosarcoidosis requires histologic confirm...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2015.06.012

    authors: MacLean HJ,Abdoli M

    更新日期:2015-09-01 00:00:00

  • Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.

    abstract:BACKGROUND:The discovery of two immunoglobulin G (IgG) antibodies against aquaporin 4 (anti-AQP4) and myelin oligodendrocyte glycoprotein (anti-MOG) has led to the distinction of the disorders anti-AQP4 immunoglobulin G positive neuromyelitis spectrum disorder (AQP4-IgG+ NMOSD) and anti-MOG associated disorder (MOGAD)....

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102718

    authors: Rempe T,Tarhan B,Rodriguez E,Viswanathan VT,Gyang TV,Carlson A,Tuna IS,Rees J

    更新日期:2020-12-24 00:00:00

  • Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement.

    abstract:BACKGROUND:Leptomeningeal inflammation is associated with increased cortical damage and worse clinical outcomes in MS. It may be detected on contrast-enhanced T2-FLAIR imaging as focal leptomeningeal contrast-enhancement (LME). OBJECTIVE:To assess the safety of intrathecal (IT) rituximab in progressive MS (PMS) and to...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.02.013

    authors: Bhargava P,Wicken C,Smith MD,Strowd RE,Cortese I,Reich DS,Calabresi PA,Mowry EM

    更新日期:2019-05-01 00:00:00

  • Flaccid paralysis in neuromyelitis optica: An atypical presentation with possible involvement of the peripheral nervous system.

    abstract:BACKGROUND:Neuromyelitis optica spectrum disorders (NMOSD) typically lead to spastic paraparesis and spare the peripheral nervous system (PNS). CASE REPORT:Here, we describe an anti-aquaporin-4-seropositive NMOSD patient suffering from acute transverse myelitis with painful, flaccid paralysis and incontinence of urine...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.07.032

    authors: Grüter T,Ayzenberg I,Gahlen A,Kneiphof J,Gold R,Kleiter I

    更新日期:2018-10-01 00:00:00

  • Prevalence of fatigue and its association with clinical features in progressive and non-progressive forms of Multiple Sclerosis.

    abstract:BACKGROUND:Fatigue is a complex and disabling symptom of Multiple Sclerosis (MS); however, there is conflicting evidence of the relationship between fatigue and clinical features of MS. Furthermore, few studies have considered these relationships specifically in a progressive MS population. AIMS:(1) estimate the preva...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.01.011

    authors: Rooney S,Wood L,Moffat F,Paul L

    更新日期:2019-02-01 00:00:00

  • Quantitative visual tests after poorly recovered optic neuritis due to multiple sclerosis.

    abstract:BACKGROUND:Visual dysfunction in MS can be quantified using a variety of tests. Many vision tests have not been formally evaluated among MS patients with existing visual dysfunction. OBJECTIVE:Evaluate several versions of visual acuity and contrast sensitivity tests, measures of central and peripheral vision, retina s...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.10.009

    authors: Longbrake EE,Lancia S,Tutlam N,Trinkaus K,Naismith RT

    更新日期:2016-11-01 00:00:00

  • Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis.

    abstract:OBJECTIVE:Infusion-associated reactions (IARs) occur in >90% patients with multiple sclerosis (MS) treated with alemtuzumab. We aimed to study the frequency of IARs at 2 sites using 5 days of steroids (1g/day of IV methylprednisolone), but otherwise distinct protocols. METHODS:This was retrospective chart review of 38...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.msard.2017.07.019

    authors: Šega-Jazbec S,Barun B,Horvat Ledinek A,Fabekovac V,Krbot Skorić M,Habek M

    更新日期:2017-10-01 00:00:00

  • Cerebral toxoplasmosis in an MS patient receiving Fingolimod.

    abstract::Multiple Sclerosis (MS) is an autoimmune disease in which lymphocytes target putative myelin antigens in the CNS, causing inflammation and neurodegeneration. Fingolimod (FTY720) is an immunosuppressive drug used as a second line therapy for relapsing forms of MS due to its safety profile and good response to treatment...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.05.004

    authors: Enriquez-Marulanda A,Valderrama-Chaparro J,Parrado L,Diego Vélez J,Maria Granados A,Luis Orozco J,Quiñones J

    更新日期:2017-11-01 00:00:00

  • COVID-19 in ocrelizumab-treated people with multiple sclerosis.

    abstract:BACKGROUND:There are limited data on the impact of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on people with multiple sclerosis (MS). OBJECTIVE:To better understand SARS-CoV-2 infection in ocrelizumab-treated people with MS. METHODS:Internal Roche/Ge...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102725

    authors: Hughes R,Whitley L,Fitovski K,Schneble HM,Muros E,Sauter A,Craveiro L,Dillon P,Bonati U,Jessop N,Pedotti R,Koendgen H

    更新日期:2020-12-30 00:00:00

  • NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS.

    abstract:BACKGROUND:Cerebrospinal fluid (CSF) levels of neurofilament light (NFL), a biomarker of axonal damage, and CXCL13, a chemokine involved in B-cell regulation, are both associated with disease activity in multiple sclerosis (MS). OBJECTIVE:To explore the potential of NFL and CXCL13 to detect residual disease activity i...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102463

    authors: Novakova L,Axelsson M,Malmeström C,Zetterberg H,Blennow K,Svenningsson A,Lycke J

    更新日期:2020-11-01 00:00:00

  • Cognitive and neuropsychiatric disorders among multiple sclerosis patients from Latin America: Results of the RELACCEM study.

    abstract:BACKGROUND:Cognitive impairment and psychiatric symptoms impact many aspects of the lives of people with multiple sclerosis [MS]. This literature is based largely on North American and Western European samples, and little is known about these aspects of MS disability in Latin America. OBJECTIVE:RELACCEM is a longitudi...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2013.10.007

    authors: Caceres F,Vanotti S,Benedict RH,RELACCEM Work Group.

    更新日期:2014-05-01 00:00:00

  • Lack of magnetic resonance imaging lesion activity as a treatment target in multiple sclerosis: An evaluation using electronically collected outcomes.

    abstract:BACKGROUND:The appropriate treatment target in multiple sclerosis (MS) is unclear. Lack of magnetic resonance imaging (MRI) lesion activity, a component of the no evidence of disease activity concept, has been proposed as a treatment target in MS. We used our MS database to investigate whether aggressively pursuing MRI...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.07.017

    authors: Conway DS,Thompson NR,Cohen JA

    更新日期:2016-09-01 00:00:00

  • Visual pathway involvement in multiple sclerosis: Look straight in the eyes.

    abstract::Visual symptoms are a common clinical manifestation of multiple sclerosis (MS) and are frequently due to acute optic neuritis (ON). However, the entire visual pathway can be involved throughout the disease course. We describe the case of a young MS patient who experienced visual symptoms that were eventually found to ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.08.008

    authors: Gaetani L,Iaccheri B,Cerquaglia A,Gentili L,Fiore T,Di Gregorio M,Mancini A,Calabresi P,Cagini C,Sarchielli P,Di Filippo M

    更新日期:2017-10-01 00:00:00